NMA Derm
Pioneering the field of Ethnic Skin since 1940.
10/09/2026
🤖🔬 AI is transforming dermatology.
New advances in PanDerm (unimodal and multimodal) and convolutional neural networks (CNN) demonstrate the growing potential of AI to enhance dermatologic diagnosis and clinical decision making, while highlighting important limitations for real-world implementation.
🔍 Can AI redefine the future of dermatology?
08/09/2026
🔬 SEBORRHEIC DERMATITIS 🔬
🎯 Seborrheic dermatitis is a chronic inflammatory skin condition that commonly affects the scalp, face, and other sebaceous areas, causing redness, scaling, and itch.
📍 In skin of color, scalp disease can present unique challenges—especially with curly/coily hair, protective styles, and less frequent washing. Roflumilast 0.3% foam is a newer FDA-approved treatment option for patients ≥9 years old.
💡 Pro tip: When using medicated shampoos, focus application on the scalp skin—not just the hair!
Comment below what disease you would like to see next! ⬇️
02/09/2026
🌟 “What’s Your Diagnosis?” Monthly Series🔍🌟Can you diagnose the skin lesion behind the dermatoscope? Let’s do a pop quiz!
Slide 1: Test your knowledge!
Guess the diagnosis in the comments below!
Slide 2: Swipe to reveal the answer and learn why!
👀 Were you surprised by today’s answer? If so, what was your diagnosis? Drop your thoughts below!
28/08/2026
Excited to bring together NMA Dermatology resident members and L’Oréal Dermatological Beauty for a special day of learning, innovation, and professional development! ✨
Residents will have the opportunity to tour the L’Oréal Research & Innovation facility, get a behind-the-scenes look at the science shaping the future of dermatology, and participate in professional development sessions designed to support them as they navigate the next stages of their careers.
Applications are now open! Click the link in our bio to apply.
🎉 Trivia Tuesdays! ✨
Plaque psoriasis is a chronic immune-mediated condition that causes raised, scaly, and sometimes itchy patches on the skin. Moderate-to-severe cases may require systemic treatment.
Icotyde (icotrokinra) is an orally administered peptide that selectively binds the IL-23 receptor, whereas Skyrizi and Tremfya are injectable monoclonal antibodies that target IL-23 itself.
This provides another approach to targeting the IL-23 pathway in people with moderate-to-severe plaque psoriasis.
dermatology skinhealth
18/08/2026
✨ Advancements in sunscreen filters are here to stay! ☀️🧴
The future of sun protection is brighter than ever. 🌞 Next-generation organic UV filters offer broader UVA and UVB protection, improved photostability, and potentially safer systemic absorption. 🌿🧬
With new filters like bemotrizinol receiving FDA approval, dermatology is entering an exciting new era of innovation in sun protection. These advances highlight the promising future of sunscreen technology and skin cancer prevention. 💙🔬
SkinCancerPrevention SunProtection FutureOfMedicine InnovationInDermatology
22/07/2026
Coming Puerto Rico for ❓
Here’s what we have in store…
Are you coming?
15/07/2026
🌟 Behind the Dermatoscope Monthly Series🔍🌟Can you identify the condition behind the dermatoscope? Let’s do a pop quiz!
Slide 1: Test your knowledge!
Guess the diagnosis in the comments below!
Slide 2: Swipe to reveal the answer and learn why!
👀 Were you surprised by today’s answer? If so, what was your diagnosis? Drop your thoughts below!
13/07/2026
Sanofi is honored to continue its partnership with NMA Dermatology, where cutting-edge science meets compassionate care. Join us at this year’s convention as we explore the future of dermatologic medicine together.
Haga clic aquí para reclamar su Entrada Patrocinada.
Categoría
Contacto la empresa
Página web
Dirección
200 Convention Boulevard
San Juan
00907
Notificaciones
Sé el primero en enterarse y déjanos enviarle un correo electrónico cuando NMA Derm publique noticias y promociones. Su dirección de correo electrónico no se utilizará para ningún otro fin, y puede darse de baja en cualquier momento.
